Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonHCHyungwoo ChoJCJason Yongsheng Chan

Discussion

Loading...

Member takes

Overview

Multinational registry reveals treatment patterns and survival rates in patients with Mantle Cell Lymphoma across Asia-Pacific, suggesting significant use of rituximab and bendamustine.

Key Points

  • To define treatment patterns and survival outcomes of newly diagnosed patients with mantle cell lymphoma in the Asia-Pacific region.
  • Multinational, multicenter prospective registry study
  • Data collected from 132 newly diagnosed MCL patients
  • Interim analysis conducted from 27 hospitals across Asia-Pacific countries
  • 2-year overall survival rate was 81.7%
  • BR regimen was most commonly used first-line treatment
  • R-CHOP was associated with inferior progression-free survival compared to BR and other regimens

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da50https://doi.org/10.1182/blood-2025-2778
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study2025
  2. 2Real-world Evidence of Treatment Outcomes in Mantle Cell Lymphoma: A Single-center Experience in Southern Taiwan2026
  3. 3Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  4. 4Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025
  5. 5Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025